{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-013080","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2024-09-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.908116+00:00","generated_at":"2026-05-31T00:45:03.500876+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeuroBo reports positive Phase 1 SAD data for DA-1726 obesity drug; no serious AEs","bullets":["45 obese participants randomized 6:3 DA-1726 vs placebo; drug safe and well tolerated.","5 AEs in DA-1726 group vs 3 placebo; no serious adverse events reported.","Dose-linear PK observed across investigated range; additional cohorts added to find max tolerated dose.","MAD Part 2 top-line data expected Q1 2025; Part 3 will evaluate early proof of concept.","CEO cites potential best-in-class profile due to balanced GLP1R and glucagon receptor activation."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-013080","json":"https://secwatch.observer/filing/0001558370-24-013080.json","markdown":"https://secwatch.observer/filing/0001558370-24-013080.md","text":"https://secwatch.observer/filing/0001558370-24-013080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024013080/0001558370-24-013080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024013080/nrbo-20240930x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T00:45:03.500876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}